Manchester Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Manchester Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28	Closed	-$1.13K	–	1316
2026 Q1	$1.13K	Hold	28	–	–	﹤0.01%	1107
2025 Q4	$704	Buy	28 +25	+833%	+$587	﹤0.01%	1209
2025 Q3	$68	Hold	3	–	–	﹤0.01%	1279
2025 Q2	$52	Hold	3	–	–	﹤0.01%	1195
2025 Q1	$66	Hold	3	–	–	﹤0.01%	1162
2024 Q4	$96	Hold	3	–	–	﹤0.01%	1144
2024 Q3	$87	Hold	3	–	–	﹤0.01%	1166
2024 Q2	$116	Hold	3	–	–	﹤0.01%	1134
2024 Q1	$177	Hold	3	–	–	﹤0.01%	1006
2023 Q4	$180	Buy	3 +1	+50%	+$51	﹤0.01%	978
2023 Q3	$77	Hold	2	–	–	﹤0.01%	1006
2023 Q2	$183	Buy	+2	New	+$173	﹤0.01%	936

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Manchester Capital Management's APLS Position: Q2 2026 in Review

Manchester Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 28 shares — an estimated $1.13K sold.

Manchester Capital Management first reported a position in APLS in Q2 2023 and held it in 12 quarters. The position peaked at $1.13K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Manchester Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Manchester Capital Management sold 28 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.13K.
Manchester Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 12 quarters.
Manchester Capital Management's Apellis Pharmaceuticals position peaked at $1.13K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.